A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients with Esophageal Adenocarcinoma.

Alexander J Byun,Rachel A Grosser,Jennie K Choe,Nabil P Rizk,Laura H Tang,Daniela Molena,Kay See Tan,David Restle,Waseem Cheema,Amy Zhu,Hans Gerdes,Arnold J Markowitz,Manjit S Bains,Valerie W Rusch,David R Jones,Prasad S Adusumilli

Annals of surgery（2023）

引用 0|浏览43

暂无评分

摘要

Pre-treatment tumor mesothelin expression is prognostic of OS for patients with locally advanced esophageal ADC, whereas serum SMRP is not a reliable biomarker for monitoring treatment response or recurrence.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要